PMID- 32354622
OWN - NLM
STAT- MEDLINE
DCOM- 20211123
LR  - 20211123
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
VI  - 34
IP  - 7
DP  - 2020 Jul
TI  - Effects of sodium glucose co-transporter 2 inhibitors on genital infections in 
      female patients with type 2 diabetes mellitus- Real world data analysis.
PG  - 107587
LID - S1056-8727(20)30339-1 [pii]
LID - 10.1016/j.jdiacomp.2020.107587 [doi]
AB  - AIMS: Sodium glucose co-transporter 2 (SGLT2) inhibitors are associated with 
      increased risk of genital infections. We aimed to assess incidence and risk 
      factors associated with genital infections among female patients with type 2 
      diabetes mellitus (T2DM) treated with SGLT2 inhibitors. METHODS: We retrieved 
      data on adult female patients with T2DM who initiated treatment with 
      empagliflozin or dapagliflozin during March 2015-March 2018, in a large Israeli 
      health maintenance organization (HMO). Genital infections were identified by 
      diagnosis codes or relevant dispensed prescriptions. The proportion of days 
      covered with SGLT2 inhibitors (SGLT2i-PDC) was measured. Univariate and 
      multivariate analyses were performed to identify risk factors. RESULTS: Of 
      1542/6153 patients, 25.1% had events of genital infections during a mean of 
      2.3 years. The adjusted hazard ratio (HR) was 4.25 for the highest versus lowest 
      SGLT2i-PDC group. Younger age, history of genital infection, and estrogen therapy 
      were associated with increased risk of genital infections. Chronic Kidney Disease 
      and DPP4 inhibitor therapy at baseline were associated with lower risk of genital 
      infections. CONCLUSIONS: Potential risk factors for genital infections were 
      identified in women initiating SGLT2 inhibitors.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Nakhleh, Afif
AU  - Nakhleh A
AD  - Diabetes and Endocrinology Clinic, Maccabi Healthcare Services, 54 Simcha Golan 
      St, Haifa, Israel; Institute of Endocrinology, Diabetes and Metabolism, Rambam 
      Health Care Campus, 8 HaAliya HaShniya St, Haifa, Israel. Electronic address: 
      anakhleh@gmail.com.
FAU - Zloczower, Moshe
AU  - Zloczower M
AD  - Institute of Endocrinology, Diabetes and Metabolism, Rambam Health Care Campus, 8 
      HaAliya HaShniya St, Haifa, Israel.
FAU - Gabay, Linoy
AU  - Gabay L
AD  - Maccabi-Kahn Institute of Research, 4 Koifman St, Tel Aviv, Israel.
FAU - Shehadeh, Naim
AU  - Shehadeh N
AD  - Diabetes and Endocrinology Clinic, Maccabi Healthcare Services, 54 Simcha Golan 
      St, Haifa, Israel; Institute of Endocrinology, Diabetes and Metabolism, Rambam 
      Health Care Campus, 8 HaAliya HaShniya St, Haifa, Israel.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200418
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Adult
MH  - Benzhydryl Compounds
MH  - Data Analysis
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Female
MH  - Glucosides
MH  - Humans
MH  - Israel
MH  - *Sodium-Glucose Transporter 2 Inhibitors/adverse effects
MH  - *Urinary Tract Infections/etiology
OTO - NOTNLM
OT  - Diabetes mellitus type 2
OT  - Genital infection
OT  - SGLT2 inhibitor
EDAT- 2020/05/02 06:00
MHDA- 2021/11/24 06:00
CRDT- 2020/05/02 06:00
PHST- 2020/03/17 00:00 [received]
PHST- 2020/04/09 00:00 [revised]
PHST- 2020/04/09 00:00 [accepted]
PHST- 2020/05/02 06:00 [pubmed]
PHST- 2021/11/24 06:00 [medline]
PHST- 2020/05/02 06:00 [entrez]
AID - S1056-8727(20)30339-1 [pii]
AID - 10.1016/j.jdiacomp.2020.107587 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2020 Jul;34(7):107587. doi: 
      10.1016/j.jdiacomp.2020.107587. Epub 2020 Apr 18.